Pathology: mML - L1 - all population;
| mML - L1 - all population | ||||||||
| CheckMate 067 (N vs I ; all population), 2015 | CheckMate 064, 2016 | CheckMate 069 (all population), 2015 | CheckMate 067 (NI vs I ; all population), 2015 | CheckMate 067 (NI vs N) EXPLORATORY, 2015 | RELATIVITY-047, 0 | A3671009, 2013 | ||
| nivolumab plus ipilimumab | 3 | T1 | T1 | T1 | ||||
| relatlimab plus nivolumab | 1 | T1 | ||||||
| nivolumab alone | 1 | T1 | T0 | T0 | ||||
| nivolumab followed by ipilimumab | 1 | T1 | ||||||
| tremelimumab | 1 | T1 | ||||||
| ipilimumab followed by nivolumab | 0 | T0 | ||||||
| ipilimumab alone | 0 | T0 | T0 | T0 | ||||
| Standard of Care (SoC) | 0 | T0 | ||||||